These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 29035708)

  • 1. An assessment of the utilization of the preclinical rodent model literature in clinical trials of putative therapeutics for the treatment of alcohol use disorders.
    Barajaz AM; Kliethermes CL
    Drug Alcohol Depend; 2017 Dec; 181():77-84. PubMed ID: 29035708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential medications for the treatment of alcohol use disorder: An evaluation of clinical efficacy and safety.
    Litten RZ; Wilford BB; Falk DE; Ryan ML; Fertig JB
    Subst Abus; 2016; 37(2):286-98. PubMed ID: 26928397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models.
    Yardley MM; Ray LA
    Addict Biol; 2017 May; 22(3):581-615. PubMed ID: 26833803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in Medications and Tailoring Treatment for Alcohol Use Disorder.
    Seneviratne C; Johnson BA
    Alcohol Res; 2015; 37(1):15-28. PubMed ID: 26259086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An institutional audit of the use of novel drugs in pediatric oncology.
    Lee J; Gillam L; Kouw S; McCarthy MC; Hansford JR
    Cancer Rep (Hoboken); 2021 Dec; 4(6):e1404. PubMed ID: 33939320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of medications for alcohol use disorders: recent advances and ongoing challenges.
    Litten RZ; Fertig J; Mattson M; Egli M
    Expert Opin Emerg Drugs; 2005 May; 10(2):323-43. PubMed ID: 15934870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery, Development, and Adoption of Medications to Treat Alcohol Use Disorder: Goals for the Phases of Medications Development.
    Litten RZ; Falk DE; Ryan ML; Fertig JB
    Alcohol Clin Exp Res; 2016 Jul; 40(7):1368-79. PubMed ID: 27184259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex Differences in Alcohol Use Disorder.
    Agabio R; Pisanu C; Gessa GL; Franconi F
    Curr Med Chem; 2017; 24(24):2661-2670. PubMed ID: 27915987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of guanfacine as a potential medication for alcohol use disorder in long-term drinking rats: behavioral and electrophysiological findings.
    Fredriksson I; Jayaram-Lindström N; Wirf M; Nylander E; Nyström E; Jardemark K; Steensland P
    Neuropsychopharmacology; 2015 Mar; 40(5):1130-40. PubMed ID: 25359257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics of alcohol use disorders and comorbid psychiatric disorders.
    Helton SG; Lohoff FW
    Psychiatry Res; 2015 Dec; 230(2):121-9. PubMed ID: 26455758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral delivery of ivermectin using a fast dissolving oral film: Implications for repurposing ivermectin as a pharmacotherapy for alcohol use disorder.
    Yardley MM; Huynh N; Rodgers KE; Alkana RL; Davies DL
    Alcohol; 2015 Sep; 49(6):553-9. PubMed ID: 26095588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing access to alcohol use disorder pharmacotherapy and treatment in primary care settings: ADaPT-PC.
    Hagedorn HJ; Brown R; Dawes M; Dieperink E; Myrick DH; Oliva EM; Wagner TH; Wisdom JP; Harris AH
    Implement Sci; 2016 May; 11():64. PubMed ID: 27164835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative utilization of pharmacotherapy for alcohol use disorder and other psychiatric disorders among U.S. Veterans Health Administration patients with dual diagnoses.
    Rubinsky AD; Chen C; Batki SL; Williams EC; Harris AH
    J Psychiatr Res; 2015 Oct; 69():150-7. PubMed ID: 26343607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Considerations for the sensible use of rodent models of inflammatory disease in predicting efficacy of new biological therapeutics in the clinic.
    Arnett HA; Viney JL
    Adv Drug Deliv Rev; 2007 Sep; 59(11):1084-92. PubMed ID: 17804112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [GABAB receptor as therapeutic target for drug addiction: from baclofen to positive allosteric modulators].
    Agabio R; Colombo G
    Psychiatr Pol; 2015; 49(2):215-23. PubMed ID: 26093587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Off-label use of psychotropic medications in pediatric wards: a prospective study].
    Winterfeld U; Le Heuzey MF; Acquaviva E; Mouren MC; Brion F; Bourdon O
    Arch Pediatr; 2009 Sep; 16(9):1252-60. PubMed ID: 19640689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics.
    Newell DR; Burtles SS; Fox BW; Jodrell DI; Connors TA
    Br J Cancer; 1999 Nov; 81(5):760-8. PubMed ID: 10555743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are Alcohol Anti-relapsing and Alcohol Withdrawal Drugs Useful in Cannabinoid Users?
    Kleczkowska P; Smaga I; Filip M; Bujalska-Zadrozny M
    Neurotox Res; 2016 Nov; 30(4):698-714. PubMed ID: 27484692
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.